Cannon Financial Strategists’s AbbVie ABBV Stock Holding History

Cannon Financial Strategists’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$906K	Buy	4,168 +27	+0.7%	+$5.99K	0.12%	54
2025 Q4	$946K	Hold	4,141	–	–	0.13%	50
2025 Q3	$959K	Hold	4,141	–	–	0.14%	51
2025 Q2	$769K	Hold	4,141	–	–	0.12%	52
2025 Q1	$868K	Hold	4,141	–	–	0.15%	49
2024 Q4	$736K	Buy	4,141 +97	+2%	+$17.8K	0.13%	51
2024 Q3	$799K	Sell	4,044 -63	-2%	-$11.8K	0.14%	53
2024 Q2	$704K	Hold	4,107	–	–	0.13%	48
2024 Q1	$748K	Buy	4,107 +100	+2%	+$17.2K	0.15%	48
2023 Q4	$621K	Hold	4,007	–	–	0.13%	50
2023 Q3	$597K	Buy	4,007 +63	+2%	+$9.25K	0.15%	48
2023 Q2	$531K	Hold	3,944	–	–	0.15%	55
2023 Q1	$629K	Hold	3,944	–	–	0.21%	40
2022 Q4	$637K	Hold	3,944	–	–	0.23%	38
2022 Q3	$529K	Sell	3,944 -212	-5%	-$30.4K	0.21%	42
2022 Q2	$637K	Buy	4,156 +90	+2%	+$13.8K	0.25%	41
2022 Q1	$659K	Buy	4,066 +156	+4%	+$22.7K	0.24%	33
2021 Q4	$529K	Hold	3,910	–	–	0.19%	44
2021 Q3	$422K	Hold	3,910	–	–	0.16%	45
2021 Q2	$440K	Hold	3,910	–	–	0.17%	42
2021 Q1	$423K	Hold	3,910	–	–	0.18%	41
2020 Q4	$419K	Sell	3,910 -112	-3%	-$10.8K	0.2%	39
2020 Q3	$352K	Buy	4,022 +112	+3%	+$10.5K	0.19%	42
2020 Q2	$384K	Hold	3,910	–	–	0.23%	37
2020 Q1	$298K	Hold	3,910	–	–	0.22%	40
2019 Q4	$346K	Hold	3,910	–	–	0.23%	38
2019 Q3	$296K	Hold	3,910	–	–	0.23%	41
2019 Q2	$284K	Hold	3,910	–	–	0.24%	37
2019 Q1	$315K	Buy	+3,910	New	+$320K	0.28%	38

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cannon Financial Strategists's ABBV Position: Q1 2026 in Review

Cannon Financial Strategists increased its AbbVie (ABBV) stake by 0.65% in Q1 2026, buying an estimated $5.99K and bringing the position to 4,168 shares worth $906K. The position accounts for 0.12% of the portfolio, ranked #54.

Cannon Financial Strategists first reported a position in ABBV in Q1 2019 and has held it in 29 quarters since. The position peaked at $959K in Q3 2025. 4,081 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Cannon Financial Strategists held 4,168 shares of AbbVie worth $906K as of Q1 2026.
Cannon Financial Strategists bought 27 AbbVie shares in Q1 2026, an estimated $5.99K.
AbbVie made up 0.12% of Cannon Financial Strategists's portfolio in Q1 2026, its #54 holding.
Cannon Financial Strategists first reported a position in AbbVie in Q1 2019 and has held it in 29 quarters since.
Cannon Financial Strategists's AbbVie position peaked at $959K in Q3 2025.
4,081 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Cannon Financial Strategists's 13F filing for Q1 2026, filed 12 May 2026.